Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer
JAMA · 04.03.2025 · 333 (9) · 774
DOI: 10.1001/jama.2024.24276 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 04.03.2025. Verfasst von Ziwei Zeng und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery (Colorectal Surgery), Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Biomedical Innovatio…. Hauptthemen laut MEDLINE: Laparoscopy, Neoplasm Recurrence, Local, Rectal Neoplasms, Transanal Endoscopic Surgery. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Previous studies have demonstrated the advantages of short-term histopathological outcomes and complications associated with transanal total mesorectal excision (TME) compared with laparoscopic TME. However, the long-term oncological outcomes of transanal TME remain ambiguous. This study aims to compare 3-year disease-free survival of transanal TME with laparoscopic TME.
Objective
To evaluate 3-year disease-free survival between transanal TME and laparoscopic TME in patients with rectal cancer. Design, Setting, and Participants This randomized, open-label, noninferiority, phase 3 clinical trial was performed in 16 different centers in China. Between April 2016 and June 2021, a total of 1115 patients with clinical stage I to III mid-low rectal cancer were enrolled. The last date of participant follow-up was in June 2024.
Interventions
Participants were randomly assigned in a 1:1 ratio before their surgical procedure to undergo either transanal TME (n = 558) or laparoscopic TME (n = 557). Main Outcomes and Measures The primary end point was 3-year disease-free survival, with a noninferiority margin of −10% for the comparison between transanal TME and laparoscopic TME. Secondary outcomes included 3-year overall survival and 3-year local recurrence.
Results
In the primary analysis set, the median patient age was 60 years. A total of 692 male and 397 female patients were included in the analysis. Three-year disease-free survival was 82.1% (97.5% CI, 78.4%-85.8%) for the transanal TME group and 79.4% (97.5% CI, 75.6%-83.4%) for the laparoscopic TME group, with a difference of 2.7% (97.5% CI, −3.0% to 8.1%). The lower tail of a 2-tailed 97.5% CI for the group difference in 3-year disease-free survival was above the noninferiority margin of −10 percentage points. Furthermore, the 3-year local recurrence was 3.6% (95% CI, 2.0%-5.1%) for transanal TME and 4.4% (95% CI, 2.6%-6.1%) for laparoscopic TME. Three-year overall survival was 92.6% (95% CI, 90.4%-94.8%) for transanal TME and 90.7% (95% CI, 88.3%-93.2%) for laparoscopic TME. Conclusions and Relevance In patients with mid-low rectal cancer, 3-year disease-free survival for transanal TME was noninferior to that of laparoscopic TME. Trial Registration ClinicalTrials.gov Identifier: NCT02966483
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of General Surgery (Colorectal Surgery), Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guang…
- Department of Colorectal Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Gastrointestinal Surgery, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
- Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, China.
- Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
- Department of Gastrointestinal Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Zitieren
APA
Zeng, Z., Luo, S., Zhang, H., Wu, M., Ma, D., Wang, Q., Xie, M., Xu, Q., Ouyang, J., Xiao, Y., Song, Y., Feng, B., Xu, Q., Wang, Y., Zhang, Y., Shi, L., Ling, L., Zhang, X., Huang, L., …, & Chinese Transanal Endoscopic Surgery Collaborative (CTESC) Group (2025). Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer. JAMA, 333(9), 774. https://doi.org/10.1001/jama.2024.24276
Vancouver
Zeng Z, Luo S, Zhang H, Wu M, Ma D, Wang Q, et al. Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer. JAMA. 2025;333(9):774. doi:10.1001/jama.2024.24276
BibTeX
@article{Zeng2025,
author = {Zeng, Ziwei and Luo, Shuangling and Zhang, Hong and Wu, Miao and Ma, Dan and Wang, Quan and Xie, Ming and Xu, Qing and Ouyang, Jun and Xiao, Yi and Song, Yongchun and Feng, Bo and Xu, Qingwen and Wang, Yanan and Zhang, Yi and Shi, Lishuo and Ling, Li and Zhang, Xingwei and Huang, Liang and Yang, Zuli and Peng, Junsheng and Wu, Xiaojian and Ren, Donglin and Huang, Meijin and Lan, Ping and Wang, Jianping and Tong, Weidong and Ren, Mingyang and Liu, Huashan and Kang, Liang and Chinese Transanal Endoscopic Surgery Collaborative (CTESC) Group, Chinese Transanal Endoscopic Surgery Collaborative (CTESC) Group},
title = {Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer},
journal = {JAMA},
year = {2025},
volume = {333},
number = {9},
pages = {774},
doi = {10.1001/jama.2024.24276}
}
EUVIMED